In the past few years, we’ve seen the biopharmaceutical industry begin to shift from a one-size-fits-all blockbuster approach toward an individualized, precision science model. This transformation has propelled companion diagnostics (CDx) into playing a more critical role than ever in the commercialization of biopharmaceutical therapeutics.
With hostile takeovers on the rise, Mike Straw argues that pharma boards have a huge role to play in managing the people issues.
Driven by knowledge advances and the importance of a more collaborative commercial model, intellectual property (IP) has morphed from an arcane, specialized function dominated by technicians to a showcase strategic priority of the “c-suite.” This trend is hardly restricted to the life sciences. In fact, some of the most creative work in using IP tools to extract more value from knowledge assets is taking place among businesses that operate across multiple sectors.
After a sharp spike in revenues, this year’s audit finds our 25 companies doubling down to secure the operational efficiencies that promise to better align with an increasingly tightfisted payer community. Never before has market relevance been so firmly linked to customer reputation.
A closer look at our Industry Audit numbers hints to a clear divide between two alternative strategies for long-term growth: scale versus focus.
New cell-culture techniques, biomanufacturing formats, and the expansion of single-use applications are driving rapid change in the biopharma market.
Specialty drug sales, record-breaking M&A paired with tax synergies, and global expansion helped to bring a new face into this year’s Pharma 50 top 10, and substantially boosted the rankings of several others.
Amid the release of our eighth list of Emerging Pharma Leaders, it's fitting to take a look at the trends and values that will determine true leadership in big Pharma in the years ahead.
The pharma industry is making progress and going through a frenzy of activity on the strategic, business, M&A and financial fronts, writes Peter Young.
Casey McDonald reports on yesterday's Healthcare Businesswoman’s AssociationWoman of the Year award ceremony in New York
William Looney reports on last week's Global Educators Network for Health Care Innovation Education meeting, focused on shared learning and best practices to drive reforms in both the public and private sectors.
Peter Young examines the positive drivers affecting the biotech industry and what happened on the M&A, IPO and financial fronts in biotech in 2014 - and what to expect in 2015.
The heart failure health area is set to expand from $2.9 billion in 2013 to $8.9 billion in 2023, writes Josh Baxt.
This year's J.P. Morgan Conference in San Francisco showed that smaller “stealth pharma” players are beginning to show solid organic growth. William Looney reports.
In a follow-up to our November CEO profile, Novo Nordisk’s Jesper Høiland writes how pharma companies and insurers are learning to collaborate.
The US is skewing young again, and the "millennials" have the clout to color everything from the nation's cultural landscape to the conduct of business practices like marketing and customer engagement, writes Bill Looney.
After a dip into negative territory in 2012, 2013 delivered a resurgence in sales revenues, but the turnaround only spotlights a larger trend: the growing divide between the big Pharmas and the more nimble players.
Pharm Exec's 2014 roster of emerging pharma leaders serves as a window on work in an industry that relies on human capital as the coinage of success, writes William Looney.
A surprising takeaway from the recent BIO Convention, writes William Looney, is the stark contrast between cooperative industry engagement and an unstable geopolitical order.
Finding the correct coordinates for big Pharma's endless cycle of re-positioning is just as important as a winning scientific hand, writes William Looney.
For those companies in this year's Pharm Exec Top 50, meeting the accelerating market demand for specialty products has become an acute strategic imperative.
Pharm Exec's Brand of the Year recipients for 2014 are multiple sclerosis treatment Copaxone and KORLYM for diseases driven by excess production of the metabolic hormone, cortisol. We profile the journey of both drugs.
Population health is the foundation for much of what is truly new in US health reform. Pharm Exec talks to Dr. David Nash, Dean of the Jefferson Medical University School of Population Health.
A study of high-performing pharma companies reveals science-based innovation strategies and patient-outcome-based commercial models are now the key drivers of growth.
Pharm Exec's latest survey of press issues shows that media coverage continues to remain on balance negative toward the industry, by a slight margin: 47% this year compared to a 46% average over the last seven years.
